Skip to main content
NASDAQ:BOLT

Bolt Biotherapeutics Competitors

$18.57
-0.22 (-1.17 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.21
$20.49
50-Day Range
$18.33
$32.91
52-Week Range
$17.30
$43.07
Volume190,531 shs
Average Volume266,144 shs
Market Capitalization$674.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Bolt Biotherapeutics (NASDAQ:BOLT) Vs. AMGN, GILD, REGN, VRTX, BIIB, and ALXN

Should you be buying BOLT stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Bolt Biotherapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Earnings and Valuation

This table compares Amgen and Bolt Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.21$7.84 billion$14.8217.03
Bolt BiotherapeuticsN/AN/AN/AN/AN/A

Amgen has higher revenue and earnings than Bolt Biotherapeutics.

Insider and Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Amgen and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Bolt BiotherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amgen and Bolt Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen291402.48
Bolt Biotherapeutics00403.00

Amgen presently has a consensus target price of $255.8571, indicating a potential upside of 1.38%. Bolt Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 115.40%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Amgen.

Summary

Amgen beats Bolt Biotherapeutics on 7 of the 9 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Gilead Sciences and Bolt Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.86$5.39 billion$6.1411.25
Bolt BiotherapeuticsN/AN/AN/AN/AN/A

Gilead Sciences has higher revenue and earnings than Bolt Biotherapeutics.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Bolt BiotherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gilead Sciences and Bolt Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences091202.57
Bolt Biotherapeutics00403.00

Gilead Sciences presently has a consensus target price of $100.5909, indicating a potential upside of 45.64%. Bolt Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 115.40%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Bolt Biotherapeutics on 7 of the 9 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Bolt Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.14$2.12 billion$21.4724.39
Bolt BiotherapeuticsN/AN/AN/AN/AN/A

Regeneron Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Regeneron Pharmaceuticals and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Bolt BiotherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Regeneron Pharmaceuticals and Bolt Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051402.74
Bolt Biotherapeutics00403.00

Regeneron Pharmaceuticals presently has a consensus target price of $656.3810, indicating a potential upside of 25.33%. Bolt Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 115.40%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Bolt Biotherapeutics on 7 of the 9 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Vertex Pharmaceuticals and Bolt Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Bolt BiotherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Vertex Pharmaceuticals and Bolt Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals041512.85
Bolt Biotherapeutics00403.00

Vertex Pharmaceuticals presently has a consensus target price of $292.00, indicating a potential upside of 34.97%. Bolt Biotherapeutics has a consensus target price of $40.00, indicating a potential upside of 115.40%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Vertex Pharmaceuticals.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Bolt Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.45$1.18 billion$4.2950.43
Bolt BiotherapeuticsN/AN/AN/AN/AN/A

Vertex Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics.

Summary

Vertex Pharmaceuticals beats Bolt Biotherapeutics on 8 of the 10 factors compared between the two stocks.

Bolt Biotherapeutics (NASDAQ:BOLT) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Profitability

This table compares Bolt Biotherapeutics and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bolt BiotherapeuticsN/AN/AN/A
Biogen35.63%51.00%23.54%

Analyst Recommendations

This is a summary of current recommendations for Bolt Biotherapeutics and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bolt Biotherapeutics00403.00
Biogen4141202.27

Bolt Biotherapeutics presently has a consensus price target of $40.00, indicating a potential upside of 115.40%. Biogen has a consensus price target of $305.5714, indicating a potential upside of 8.98%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bolt Biotherapeutics is more favorable than Biogen.

Institutional & Insider Ownership

83.5% of Biogen shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Bolt Biotherapeutics and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt BiotherapeuticsN/AN/AN/AN/AN/A
Biogen$14.38 billion2.94$5.89 billion$33.578.35

Biogen has higher revenue and earnings than Bolt Biotherapeutics.

Summary

Biogen beats Bolt Biotherapeutics on 7 of the 9 factors compared between the two stocks.

Bolt Biotherapeutics (NASDAQ:BOLT) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Profitability

This table compares Bolt Biotherapeutics and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bolt BiotherapeuticsN/AN/AN/A
Alexion Pharmaceuticals16.32%23.16%14.76%

Analyst Recommendations

This is a summary of current recommendations for Bolt Biotherapeutics and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bolt Biotherapeutics00403.00
Alexion Pharmaceuticals015402.21

Bolt Biotherapeutics presently has a consensus price target of $40.00, indicating a potential upside of 115.40%. Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 8.83%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bolt Biotherapeutics is more favorable than Alexion Pharmaceuticals.

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Bolt Biotherapeutics and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt BiotherapeuticsN/AN/AN/AN/AN/A
Alexion Pharmaceuticals$4.99 billion7.74$2.40 billion$9.7417.94

Alexion Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics.

Summary

Alexion Pharmaceuticals beats Bolt Biotherapeutics on 6 of the 8 factors compared between the two stocks.


Bolt Biotherapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$252.38-0.4%$145.01 billion$23.36 billion20.35Ex-Dividend
Analyst Report
Gilead Sciences logo
GILD
Gilead Sciences
2.8$69.07-0.8%$86.63 billion$22.45 billion71.21
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$523.73-1.4%$56.11 billion$7.86 billion19.14
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$216.35-0.3%$56.01 billion$4.16 billion27.32
Biogen logo
BIIB
Biogen
1.5$280.40-0.1%$42.22 billion$14.38 billion9.28
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$174.75-0.7%$38.62 billion$4.99 billion40.83
Seagen logo
SGEN
Seagen
1.7$147.98-0.3%$26.85 billion$916.71 million58.26Analyst Report
Incyte logo
INCY
Incyte
1.6$82.27-0.4%$18.09 billion$2.16 billion-52.40
Exact Sciences logo
EXAS
Exact Sciences
2.0$94.67-2.2%$16.24 billion$876.29 million-42.84Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89-0.1%$15.97 billion$219.75 million-17.36Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34-0.5%$14.13 billion$1.70 billion17.70
Novavax logo
NVAX
Novavax
1.8$140.16-6.0%$10.39 billion$18.66 million-26.85Earnings Announcement
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$165.87-3.7%$9.11 billion$270.24 million202.28
United Therapeutics logo
UTHR
United Therapeutics
1.5$198.29-0.2%$8.88 billion$1.45 billion18.76
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.08-1.6%$8.80 billion$788.10 million100.09
Exelixis logo
EXEL
Exelixis
1.9$25.24-1.3%$7.91 billion$967.78 million52.58Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.7$42.42-1.4%$6.04 billion$195.99 million265.13Earnings Announcement
Analyst Report
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32-2.5%$5.26 billion$1.12 billion77.75Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89-0.9%$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08-0.8%$3.54 billion$1.17 billion-48.00
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29-2.8%$3.23 billion$1.11 billion19.39
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$14.38-10.7%$2.56 billion$48.83 million-18.92
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.23-2.8%$2.46 billion$182.24 million-8.03Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$3.61-2.5%$2.42 billion$901.90 million-20.05
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$134.00-0.5%$2.22 billionN/A-12.10Analyst Report
Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$125.17-3.5%$2.08 billion$120.28 million-126.43
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.03-1.3%$2.08 billion$638.60 million-10.40
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.85-1.4%$1.91 billion$428.41 million17.17
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.89-0.4%$1.57 billion$102.43 million-18.15
Curis logo
CRIS
Curis
1.1$15.05-9.8%$1.38 billion$10 million-18.35Earnings Announcement
Analyst Revision
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.71-0.6%$1.34 billion$82.27 million-16.37Earnings Announcement
Innoviva logo
INVA
Innoviva
1.1$12.77-0.8%$1.29 billion$261.02 million6.52
Codexis logo
CDXS
Codexis
1.5$18.18-0.6%$1.17 billion$68.46 million-51.94
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.38-1.1%$1.08 billion$3.57 million-12.28
MannKind logo
MNKD
MannKind
1.4$4.23-1.9%$1.05 billion$63.04 million-20.14Earnings Announcement
Analyst Revision
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.58-0.4%$1.03 billion$227.19 million51.61
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.76-0.5%$889.20 million$35.22 million-5.66Gap Down
Agenus logo
AGEN
Agenus
1.6$3.26-0.9%$725.16 million$150.05 million-2.99
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$9.89-5.6%$689.83 million$36.13 million-14.76
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.13-1.3%$674.59 million$150,000.00-4.47
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.68-0.8%$626.20 million$59.29 million-24.53
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.87-0.0%$613.80 million$143.01 million-1.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.23-2.4%$610.76 million$322.07 million-4.03Analyst Revision
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$17.26-5.2%$572.38 million$252 million-1.76
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.44-1.2%$535.65 million$109.33 million-2.53Earnings Announcement
Verastem logo
VSTM
Verastem
1.5$2.94-0.0%$505.44 million$17.46 million-2.09Earnings Announcement
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.29-5.2%$464.97 million$22.27 million-4.06Earnings Announcement
Geron logo
GERN
Geron
1.4$1.43-0.0%$455.55 million$460,000.00-4.09Analyst Upgrade
Analyst Revision
XOMA logo
XOMA
XOMA
1.5$30.75-2.7%$346.55 million$18.37 million-27.70Analyst Revision
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.54-4.0%$344.28 million$36.63 million-4.16News Coverage
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.